PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

This study is currently recruiting participants.

Verified March 2013 by Hoosier Oncology Group

Sponsor:

Collaborator:

Clovis Oncology, Inc.

Information provided by (Responsible Party):

Hoosier Oncology Group

ClinicalTrials.gov Identifier:

NCT01074970

First received: February 23, 2010

Last updated: March 6, 2013

Last verified: March 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)